Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1997 Feb;65(2):640–644. doi: 10.1128/iai.65.2.640-644.1997

Oral immunization with PspA elicits protective humoral immunity against Streptococcus pneumoniae infection.

M Yamamoto 1, L S McDaniel 1, K Kawabata 1, D E Briles 1, R J Jackson 1, J R McGhee 1, H Kiyono 1
PMCID: PMC176108  PMID: 9009325

Abstract

Streptococcus pneumoniae is a major respiratory mucosal pathogen affecting infants and children. Although a polysaccharide-based vaccine has been useful in adult populations, it does not elicit protective immunity in infants and young children. Pneumococcal surface protein A (PspA) is a highly immunogenic surface protein produced by all strains of Streptococcus pneumoniae. Previous studies have shown that systemic immunization of mice with PspA can elicit protective immunity against fatal pneumococcal infection. In this study, we demonstrated that oral immunization with PspA could elicit protective immune responses against pneumococcal infection. When mice were orally immunized with PspA alone, low levels of PspA-specific immunoglobulin G (IgG) responses were induced in serum; none was induced in secretion. On the other hand, when PspA was given orally with the mucosal adjuvant cholera toxin (CT), significant levels of IgG and IgA anti-PspA responses were induced in serum. The major IgG subclass was IgG1, followed by IgG2b, a profile of antibody response supported by Th2-type cells. In addition, all mice orally immunized with PspA and CT were protected from the lethal challenge with capsular serotype 3 S. pneumoniae A66. These results suggested that an oral PspA vaccine may be a useful means of preventing pneumococcal disease.

Full Text

The Full Text of this article is available as a PDF (203.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benton K. A., Everson M. P., Briles D. E. A pneumolysin-negative mutant of Streptococcus pneumoniae causes chronic bacteremia rather than acute sepsis in mice. Infect Immun. 1995 Feb;63(2):448–455. doi: 10.1128/iai.63.2.448-455.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Berry A. M., Lock R. A., Hansman D., Paton J. C. Contribution of autolysin to virulence of Streptococcus pneumoniae. Infect Immun. 1989 Aug;57(8):2324–2330. doi: 10.1128/iai.57.8.2324-2330.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Berry A. M., Yother J., Briles D. E., Hansman D., Paton J. C. Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect Immun. 1989 Jul;57(7):2037–2042. doi: 10.1128/iai.57.7.2037-2042.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Briles D. E., King J. D., Gray M. A., McDaniel L. S., Swiatlo E., Benton K. A. PspA, a protection-eliciting pneumococcal protein: immunogenicity of isolated native PspA in mice. Vaccine. 1996 Jun;14(9):858–867. doi: 10.1016/0264-410x(96)82948-3. [DOI] [PubMed] [Google Scholar]
  5. Burke J. P., Klein J. O., Gezon H. M., Finland M. Pneumococcal bacteremia. Review of 111 cases, 1957--1969, with special reference to cases with undetermined focus. Am J Dis Child. 1971 Apr;121(4):353–359. [PubMed] [Google Scholar]
  6. Cowan M. J., Ammann A. J., Wara D. W., Howie V. M., Schultz L., Doyle N., Kaplan M. Pneumococcal polysaccharide immunization in infants and children. Pediatrics. 1978 Nov;62(5):721–727. [PubMed] [Google Scholar]
  7. Crain M. J., Waltman W. D., 2nd, Turner J. S., Yother J., Talkington D. F., McDaniel L. S., Gray B. M., Briles D. E. Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae. Infect Immun. 1990 Oct;58(10):3293–3299. doi: 10.1128/iai.58.10.3293-3299.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Elson C. O., Ealding W. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J Immunol. 1984 Jun;132(6):2736–2741. [PubMed] [Google Scholar]
  9. Gray B. M., Dillon H. C., Jr, Briles D. E. Epidemiological studies of Streptococcus pneumoniae in infants: development of antibody to phosphocholine. J Clin Microbiol. 1983 Nov;18(5):1102–1107. doi: 10.1128/jcm.18.5.1102-1107.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gray B. M. Pneumococcal infections in an era of multiple antibiotic resistance. Adv Pediatr Infect Dis. 1996;11:55–99. [PubMed] [Google Scholar]
  11. Hensel A., Stockhofe-Zurwieden N., Petzoldt K., Lubitz W. Oral immunization of pigs with viable or inactivated Actinobacillus pleuropneumoniae serotype 9 induces pulmonary and systemic antibodies and protects against homologous aerosol challenge. Infect Immun. 1995 Aug;63(8):3048–3053. doi: 10.1128/iai.63.8.3048-3053.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jackson R. J., Fujihashi K., Kiyono H., McGhee J. R. Luminometry: a novel bioluminescent immunoassay enhances the quantitation of mucosal and systemic antibody responses. J Immunol Methods. 1996 Apr 19;190(2):189–197. doi: 10.1016/0022-1759(95)00276-6. [DOI] [PubMed] [Google Scholar]
  13. Jackson R. J., Fujihashi K., Xu-Amano J., Kiyono H., Elson C. O., McGhee J. R. Optimizing oral vaccines: induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect Immun. 1993 Oct;61(10):4272–4279. doi: 10.1128/iai.61.10.4272-4279.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kiyono H., Bienenstock J., McGhee J. R., Ernst P. B. The mucosal immune system: features of inductive and effector sites to consider in mucosal immunization and vaccine development. Reg Immunol. 1992 Mar-Apr;4(2):54–62. [PubMed] [Google Scholar]
  15. Langermann S., Palaszynski S. R., Burlein J. E., Koenig S., Hanson M. S., Briles D. E., Stover C. K. Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A. J Exp Med. 1994 Dec 1;180(6):2277–2286. doi: 10.1084/jem.180.6.2277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lycke N., Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology. 1986 Oct;59(2):301–308. [PMC free article] [PubMed] [Google Scholar]
  17. Marinaro M., Staats H. F., Hiroi T., Jackson R. J., Coste M., Boyaka P. N., Okahashi N., Yamamoto M., Kiyono H., Bluethmann H. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol. 1995 Nov 15;155(10):4621–4629. [PubMed] [Google Scholar]
  18. McDaniel L. S., Scott G., Kearney J. F., Briles D. E. Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae. J Exp Med. 1984 Aug 1;160(2):386–397. doi: 10.1084/jem.160.2.386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. McDaniel L. S., Scott G., Widenhofer K., Carroll J. M., Briles D. E. Analysis of a surface protein of Streptococcus pneumoniae recognised by protective monoclonal antibodies. Microb Pathog. 1986 Dec;1(6):519–531. doi: 10.1016/0882-4010(86)90038-0. [DOI] [PubMed] [Google Scholar]
  20. McDaniel L. S., Sheffield J. S., Delucchi P., Briles D. E. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type. Infect Immun. 1991 Jan;59(1):222–228. doi: 10.1128/iai.59.1.222-228.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. McDaniel L. S., Waltman W. D., 2nd, Gray B., Briles D. E. A protective monoclonal antibody that reacts with a novel antigen of pneumococcal teichoic acid. Microb Pathog. 1987 Oct;3(4):249–260. doi: 10.1016/0882-4010(87)90058-1. [DOI] [PubMed] [Google Scholar]
  22. McDaniel L. S., Yother J., Vijayakumar M., McGarry L., Guild W. R., Briles D. E. Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA). J Exp Med. 1987 Feb 1;165(2):381–394. doi: 10.1084/jem.165.2.381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. McGowan J. E., Jr, Bratton L., Klein J. O., Finland M. Bacteremia in febrile children seen in a "walk-in" pediatric clinic. N Engl J Med. 1973 Jun 21;288(25):1309–1312. doi: 10.1056/NEJM197306212882501. [DOI] [PubMed] [Google Scholar]
  24. Orcel B., Delclaux B., Baud M., Derenne J. P. Oral immunization with bacterial extracts for protection against acute bronchitis in elderly institutionalized patients with chronic bronchitis. Eur Respir J. 1994 Mar;7(3):446–452. doi: 10.1183/09031936.94.07030446. [DOI] [PubMed] [Google Scholar]
  25. Talkington D. F., Crimmins D. L., Voellinger D. C., Yother J., Briles D. E. A 43-kilodalton pneumococcal surface protein, PspA: isolation, protective abilities, and structural analysis of the amino-terminal sequence. Infect Immun. 1991 Apr;59(4):1285–1289. doi: 10.1128/iai.59.4.1285-1289.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Tart R. C., McDaniel L. S., Ralph B. A., Briles D. E. Truncated Streptococcus pneumoniae PspA molecules elicit cross-protective immunity against pneumococcal challenge in mice. J Infect Dis. 1996 Feb;173(2):380–386. doi: 10.1093/infdis/173.2.380. [DOI] [PubMed] [Google Scholar]
  27. Teele D. W., Pelton S. I., Grant M. J., Herskowitz J., Rosen D. J., Allen C. E., Wimmer R. S., Klein J. O. Bacteremia in febrile children under 2 years of age: results of cultures of blood of 600 consecutive febrile children seen in a "walk-in" clinic. J Pediatr. 1975 Aug;87(2):227–230. doi: 10.1016/s0022-3476(75)80584-1. [DOI] [PubMed] [Google Scholar]
  28. Van Damme M., Sory M. P., Biot T., Vaerman J. P., Cornelis G. R. Oral immunization against cholera toxin with a live Yersinia enterocolitica carrier in mice. Gastroenterology. 1992 Aug;103(2):520–531. doi: 10.1016/0016-5085(92)90842-m. [DOI] [PubMed] [Google Scholar]
  29. Xu-Amano J., Jackson R. J., Fujihashi K., Kiyono H., Staats H. F., McGhee J. R. Helper Th1 and Th2 cell responses following mucosal or systemic immunization with cholera toxin. Vaccine. 1994 Aug;12(10):903–911. doi: 10.1016/0264-410x(94)90033-7. [DOI] [PubMed] [Google Scholar]
  30. Xu-Amano J., Kiyono H., Jackson R. J., Staats H. F., Fujihashi K., Burrows P. D., Elson C. O., Pillai S., McGhee J. R. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J Exp Med. 1993 Oct 1;178(4):1309–1320. doi: 10.1084/jem.178.4.1309. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Yother J., White J. M. Novel surface attachment mechanism of the Streptococcus pneumoniae protein PspA. J Bacteriol. 1994 May;176(10):2976–2985. doi: 10.1128/jb.176.10.2976-2985.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES